Skip to main content

Table 2 PH Cox regression univariate analyses for the association of gene SPAG5 with endocrine therapy and chemotherapy

From: The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy

  RFS OS DMFS
n HR P-value n HR P-value n HR P-value
Systemic therapy subtypes
 Endo 849 1.57 (1.2–2.06) 0.001 128 2 (1.05–3.8) 0.03 513 2.36 (1.57–3.54) < 0.001
 Tamoxifen-only 739 1.57 (1.17–2.12) 0.0027 114 2.13 (1–4.52) 0.044 556 2.23 (1.52–3.26) < 0.001
 Chemo 274 1.1 (0.74–1.63) 0.64 69 1.54 (0.74–3.2) 0.25 65 1.49 (0.65–3.4) 0.34
 Endo + chemo 171 2.77 (1.37–5.6) 0.0032 34 4.28 (0.48–38.33) 0.16 86 1.96 (0.66–5.86) 0.22
  1. Endo Endocrine therapy, chemo Chemotherapy